New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows
UCLA
Based on the study, researchers also created an online risk calculator that forecasts the probability of overall and progression-free survival in response to LuPSMA. Denise Heady |
July 8, 2021
A new prognostic tool developed by researchers from the UCLA Jonsson Comprehensive Cancer Center and five other institutions helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.
The tool, described in a study published today in Lancet Oncology, analyzes a wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.
Tool helps predicts who will respond best to targeted prostate cancer therapy scienceblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblog.com Daily Mail and Mail on Sunday newspapers.